Studies investigating the PI3K inhibitor XL146, the AKT inhibitor GSK690693 and the mTOR inhibitor MLN0128 all demonstrated modest anti-tumor activity in preclinical models [104–106]. Here, PIK3CD is linked to neoplasm.